Detection of serum p53 antibodies in patients with esophageal squamous cell carcinoma: Correlation with clinicopathologic features and tumor markers

Oncology Reports

Volumn 5, Issue 4, 1998, Pages 871-874

  Shimada, Hideaki ^a   Nakajima, Kazuaki ^a   Ochiai, Takenori ^a   Koide, Yoshio ^a   Okazumi, Shin Ichi ^a   Matsubara, Hisahiro ^a   Takeda, Akihiko ^a   Miyazawa, Yukimasa ^a   Arima, Miwako ^a   Isono, Kaichi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Esophageal cancer; Serum p53 antibody; Squamous cell carcinoma; Tumor marker

Indexed keywords

CANCER ANTIBODY; CARCINOEMBRYONIC ANTIGEN; PROTEIN P53; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL FEATURE; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 13144250129     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.4.871     Document Type: Article

References (18)

1. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
2. Soussi T, Legros Y, Lubin R, Ory K and Schlichtholz B: Multifactorial analysis of p53 alteration in human cancer: A review. Int J Cancer 57: 1-9, 1994.
3. Hollstein MC, Metcalf RA, Welsh JA, Montesano R and Harris CC: Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 87: 9958-9961, 1987.
4. Sarbia M, Forschen R, Borchard F, Horstmann O and Willers R: p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 74: 2218-2223, 1994.
5. Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, Buffa R, Ferro S, Piazza M, Blandamura S, Segalin A, Bonavian L and Peracchia A: p53 protein accumulation and p53 gene mutation in esophageal carcinoma. Cancer 79: 425-432, 1997.
6. De Fromentel C, May-Levin F, Mouriesse H, Lemerle J, Chandrasekaran K and May P: Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 30: 403-408, 1987.
7. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA and Bunting PS: Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58: 480-487, 1994.
8. Winter S, Minna JD, Johnson BE, Takashi T, Gazdar AF and Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type p53 mutation. Cancer Res 532: 4168-4174, 1992.
9. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirscg A and Soussi T: Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant region in the p53 protein. Br J Cancer 69: 809-816, 1994.
10. Lubin R, Zalcman G, Bouchet L, Tredaniel J, Legros Y, Cazals D, et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1: 701-702, 1995.
11. Von Brevern MC, Hollstein MC, Cawley HM, De Benedetti VMG, Bennett WP, Liang L, He AG, Zhu SM, Tursz T, Janin N and Trivers GE: Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly m individuals with p53 core domain mutations in their tumors. Cancer Res 56: 4917-4621, 1996.
12. Hirata S, Yamazaki K, Yokoyama Y, Ueda M, Kubo Y and Samejima N: Studies on antigen associated with human squamous cell carcinoma (SCC antigen) in patients with esophageal carcinoma. Nippon Geka Gakkai Zasshi 90: 267-272, 1989.
13. Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T and Suzuki T: CYFRA21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 79: 1647-1655, 1997.
14. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B and Roth JA: p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 51: 4495-4499, 1991.
15. UICC TNM Classification of Malignant Tumors, 5th edition. Sobin LH and Wittekind Ch (eds). A John Wiley & Sons, Inc., Publication, 1997.
16. Flejou JF, Potet F, Muzeau F, Le Pelletier F, Fekete F and Henin D: Overexpression of p53 protein m Barrett's syndrome with malignant transformation. J Clin Pathol 46: 330-333, 1993.
17. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J and Soussi T: Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 345: 621-622, 1995.
18. Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, Talbot M, Marandas P, Schwaab G, Wibault P, Luboinski B, Eshwege F and Soussi T: Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 88: 1228-1233, 1996.